about
Citability of original research and reviews in journals and their sponsored supplementsHostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studiesManaging Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency SettingUnmet needs in the treatment of schizophrenia: new targets to help different symptom domainsViolent patients in the emergency settingA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions.GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implicationsCost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics.A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do.How to efficiently maintain your own electronic resource library.Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital.The Sunshine Act and Transfers of Value: Impact on Non-industry Authorship.Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Antipsychotic use varies by patient age.Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.Impact factor? Shmimpact factor!: the journal impact factor, modern day literature searching, and the publication processEffectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents.Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Pharmacokinetics of aripiprazole and concomitant lithium and valproate.Beyond PubMed: Searching the "Grey Literature" for Clinical Trial Results.Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.A review of new atypical antipsychotic launches in the United States.
P50
Q21091143-ED1072A1-42EC-40EF-B197-32200E85932AQ24289439-FC2340A4-6B51-4E06-9734-A0A841490ED6Q26765899-E4043067-97DD-40AA-A5B1-364FC7207C68Q26991750-22619EEA-F357-496A-A47F-283AEC65B22AQ28142035-002DEC94-CBA7-4657-B33D-AEB117D0595DQ30353864-7B44B70D-C615-4FB0-AC36-E27404946CFDQ30370326-CCF66D4C-DEFC-411F-904F-E2EC62E27AF2Q30374976-E051C071-8732-47F7-A93B-6B61473115F6Q30376372-63FCE286-E873-4E7B-B457-B1355D2C498AQ30486907-5D1A4D9B-CBE9-462B-B55B-175AAB501F0EQ30487038-BB3F1007-9017-4D7D-94E1-7D8D2FCE479AQ30785262-2C1DCEC6-2A26-455A-B757-95930E2F1FCAQ33198820-0025F5DA-0A4C-4019-AD01-4FCB3CCC3CE4Q33213938-3F0C4573-F3E5-4B71-84B1-BECDAD138126Q33222734-146F0C45-78FA-48C6-B08C-D584567BA9CAQ33241969-6BDE0F3A-ED1A-4B90-9C97-CEFA6201D7E0Q33502329-52CCD4DD-1256-4FB5-BFCF-51D44B496DEEQ33535581-063BFBE0-B847-43ED-9F5A-0EA0D6F21797Q33557600-674AC88D-A17B-4957-A572-B777443077E9Q33559333-DC2DF08A-722D-47E4-805D-19FD0543E611Q33586358-607E0BB6-BDA2-41B6-81D5-44CF1293C836Q33826250-5276F2B7-57B6-4F02-A3ED-F6525C865116Q33894639-1EC9A2BC-AF91-4708-B86F-A77BD82CB6B1Q34037630-C00BD91D-7451-4B4F-A7BF-5FF4937A1B61Q34064593-3CA4F1D0-18F6-4507-A455-8A10AC808A35Q34073723-B2044CC5-2512-41E4-8B32-803E0ED3D746Q34097289-BF4E0212-0ADB-4FD7-ADD1-70B61B99249EQ34201539-DA74E193-58C0-4405-8181-A5670269589FQ34224372-CEAADC60-3163-427F-A4B2-D77F9FF6DFBFQ34226261-D05A1B96-0395-4BC8-896B-EFA4965037CAQ34252774-94B985E0-5206-45EC-B243-6588B249207CQ34322714-616313A7-F468-4802-A5FA-38A640957450Q34325164-7F1E84B0-3307-453E-BB80-7B980A778B5BQ34335555-16AA3C32-FB34-47BB-87A2-8792512DD6CCQ34347796-D213559B-02D2-4FC4-9B16-5855CDEFC397Q34369664-733FBFD0-D8B5-4C0B-9A16-E86EBFBD1445Q34376865-BBC40800-A754-425F-9E1B-4B6EE17ED6ECQ34377470-596D821A-7A6B-4A2E-A3E0-B01E6984628EQ34501911-CBBF6EAA-DB58-42EC-A0BB-0293846988F7Q34527733-0C961718-A10F-418D-A9FC-229409D657D6
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Leslie Citrome
@ast
Leslie Citrome
@en
Leslie Citrome
@es
Leslie Citrome
@fr
Leslie Citrome
@nl
Leslie Citrome
@sl
type
label
Leslie Citrome
@ast
Leslie Citrome
@en
Leslie Citrome
@es
Leslie Citrome
@fr
Leslie Citrome
@nl
Leslie Citrome
@sl
prefLabel
Leslie Citrome
@ast
Leslie Citrome
@en
Leslie Citrome
@es
Leslie Citrome
@fr
Leslie Citrome
@nl
Leslie Citrome
@sl
P214
P106
P1153
7006352802
P2038
Leslie_Citrome
P21
P214
P31
P496
0000-0002-6098-9266
P735
P7859
lccn-n2004121242